Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.64 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654029 | 0.95 | KDR (0.57) | KDREPHA2EPHB4ERBB2EGFR | |
| SCHEMBL5653360 | 0.89 | KDR (0.65) | KDREPHA2EPHB4ERBB2ACHE | |
| SCHEMBL5649066 | 0.85 | KDR (0.58) | KDREGFR | |
| SCHEMBL5651585 | 0.84 | KDR (0.55) | KDREPHA2EPHB4EGFR | |
| SCHEMBL5648562 | 0.82 | KDR (0.56) | KDRERBB2EGFR | |
| SCHEMBL5649229 | 0.82 | KDR (0.65) | KDREPHA2ERBB2EGFR | |
| SCHEMBL5652981 | 0.82 | KDR (0.57) | KDREPHA2EPHB4EGFR | |
| SCHEMBL5648577 | 0.81 | KDR (0.64) | KDREGFR | |
| SCHEMBL5648569 | 0.81 | KDR (0.61) | KDREGFR | |
| SCHEMBL5650446 | 0.80 | KDR (0.65) | KDREPHA2ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | KDR 1/4885EPHA2 814/4885EPHB4 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.